Entecavir

Introduction Overview

Generic Name

entecavir

Brand Name

Baraclude

Dosage Form

oral solution (0.05 mg/mL), oral tablet (0.5 mg; 1 mg)

Drug Class

Nucleoside reverse transcriptase inhibitors (NRTIs)

Pharmacokinetics

Absorption:
Entecavir exhibits high oral bioavailability when administered on an empty stomach, with the extent of absorption being approximately 100%. The drug should ideally be taken at least 2 hours after a meal and at least 2 hours before a subsequent meal to optimize absorption, as food intake can reduce its bioavailability by approximately 20%. The pharmacokinetics of entecavir are linear over the usual dose range, with peak plasma concentrations (Cmax) generally reached within 0.5 to 1.5 hours post-dose in fasting conditions. The oral solution allows precise dosing especially in pediatric populations and enhances absorption convenience.

Distribution:
Entecavir displays a volume of distribution (Vd) that indicates widespread distribution throughout the body tissues, including liver cells where hepatitis B virus (HBV) resides and replicates. Binding to plasma proteins is minimal, less than 13%, which facilitates free drug availability for antiviral activity. Tissue distribution studies suggest entecavir achieves effective intracellular concentrations critical for viral suppression. The drug’s ability to penetrate hepatocytes ensures potent antiviral effect. Entecavir crosses the placenta and is excreted in breast milk, warranting caution during pregnancy and lactation.

Metabolism:
Entecavir undergoes minimal metabolism; it is largely excreted unchanged. Unlike many nucleoside analogues, it does not require hepatic biotransformation to an active metabolite, decreasing variability in response due to liver metabolic activity. This minimal metabolism reduces potential drug-drug interactions mediated by cytochrome P450 enzymes. Intracellularly, entecavir is phosphorylated by host kinases to its active triphosphate form which inhibits HBV DNA polymerase.

Elimination:
Primary elimination of entecavir is renal, with approximately 70-90% of an oral dose excreted unchanged in the urine. The plasma elimination half-life ranges from 128 to 149 hours due to the long intracellular half-life of its active triphosphate form. Renal clearance is via tubular secretion and glomerular filtration; thus, dose adjustments are necessary in patients with renal impairment to avoid toxicity. The long half-life contributes to once-daily dosing convenience. There is negligible biliary excretion or fecal elimination. Hemodialysis can remove some amount of entecavir, and supplemental dosing may be required in patients undergoing dialysis.

Dosage Forms

Available Dosage Forms:
Entecavir is available in the following oral formulations:
- Oral solution: 0.05 mg/mL concentration contained in bottles with a measuring device for accurate dosing in pediatric and adult patients who require dose flexibility.
- Oral tablets: film-coated tablets available in 0.5 mg and 1 mg strengths for ease of administration and dose adjustments based on clinical response.

Dosages for Adults and Adolescents:
The usual adult dose for chronic hepatitis B varies depending on treatment history and presence of viral resistance. For nucleoside-naïve adults and adolescents aged 16 years and older, the typical dose is 0.5 mg orally once daily on an empty stomach. In patients with lamivudine resistance, a higher dose of 1 mg daily is recommended. The treatment duration is typically long-term, potentially several years, depending on virological response and clinical assessment.

Specific Patient Populations:
- Pediatric patients aged 2 years and older and weighing at least 10 kg (22 lbs): Dosing is weight-based and may require the oral solution to achieve appropriate exposures.
- Patients with renal impairment: Dose reductions or extended dosing intervals are essential, based on creatinine clearance, due to predominant renal excretion.
- Patients undergoing hemodialysis: Supplementary dosing after dialysis sessions is recommended.
- Liver transplant recipients and patients with severe liver dysfunction: Careful monitoring and dose adjustments as per clinical judgment.
- Pregnant and breastfeeding women: Should consult healthcare providers; entecavir crosses placenta and is excreted in breast milk. Pregnancy registry enrollment is encouraged.

Given these formulations and concentrations, entecavir allows precise dosing tailored to individual patient characteristics ensuring optimized antiviral therapy with manageable safety profile.

Mechanism Of Action

Entecavir is a potent, selective nucleoside analogue of deoxyguanosine that exerts its antiviral effects against hepatitis B virus (HBV) primarily by inhibiting the viral reverse transcriptase enzyme. Structurally, entecavir is phosphorylated intracellularly by host kinases to its active triphosphate form, which competes with the natural substrate deoxyguanosine triphosphate for incorporation into viral DNA. This leads to the inhibition of multiple functions of HBV polymerase, including base priming, reverse transcription of the negative strand, and synthesis of the positive strand of HBV DNA.

The inhibition of HBV DNA polymerase prevents viral replication and decreases circulating HBV DNA levels in the blood. This results in suppression of viral load, reduction of liver inflammation, and ultimately lowers disease progression associated with chronic hepatitis B infection. Entecavir’s high selectivity for viral polymerase over host cellular DNA polymerases contributes to its favorable safety profile and low incidence of mitochondrial toxicity often seen with other nucleoside analogues.

Comparatively, entecavir demonstrates greater potency and a higher genetic barrier to resistance than lamivudine, another nucleoside reverse transcriptase inhibitor used in HBV treatment. Clinical studies have shown that entecavir more effectively suppresses HBV replication and delays the emergence of resistant viral strains, making it a preferred agent in many treatment guidelines.

Research evidence from randomized controlled trials underscores entecavir’s ability to significantly reduce HBV DNA levels, normalize alanine transaminase (ALT) levels, and improve liver histology over prolonged therapy. Its mechanism also helps in reducing the risk of hepatic fibrosis and cirrhosis development, affirming its role as a foundational antiviral agent in chronic hepatitis B management.

Pharmacological Actions

Inhibition of hepatitis B virus (HBV) DNA polymerase enzyme activity.
Suppression of viral replication through competitive inhibition of reverse transcriptase.
Intracellular phosphorylation to active triphosphate form enabling incorporation into viral DNA.
Reduction of circulating HBV DNA viral load and serum HBV DNA levels.
Prevention of HBV DNA chain elongation resulting in premature termination of viral DNA synthesis.
High selectivity for viral polymerase with minimal effect on human DNA polymerases.
Demonstrates potent antiviral activity with a high genetic barrier to resistance.
Improves liver function tests by reducing hepatocellular injury.
Provides effective viral suppression in both nucleoside-naïve and lamivudine-resistant HBV strains.
Exhibits minimal mitochondrial toxicity compared to other nucleoside analogues.
Maintains long intracellular half-life of active metabolite to support once-daily dosing.
Contributes to histological improvement and reduced progression of liver fibrosis and cirrhosis.

Therapeutic Or Clinical Uses

Treatment of chronic hepatitis B virus infection in adults and pediatric patients aged 2 years and older.
Management of both nucleoside-naïve and lamivudine-resistant hepatitis B virus strains.
Suppression of HBV viral replication to reduce liver inflammation and progression to cirrhosis.
Prevention of HBV reactivation in patients with prior HBV history undergoing immunosuppressive therapy.
Long-term viral load control to decrease the risk of hepatocellular carcinoma development.
Use in patients with compensated and decompensated liver disease due to chronic hepatitis B.
Post-liver transplant therapy in HBV-infected patients to prevent graft reinfection.
Potential off-label use in combination regimens for multidrug-resistant hepatitis B virus infections.
Reduction of hepatic fibrosis and enhancement of liver histological parameters.
Maintenance therapy to prevent hepatic flare-ups following viral suppression.
Treatment regimen option where interferon therapy is contraindicated or not tolerated.
Use in pediatric patients weighing at least 10 kilograms to manage chronic hepatitis B.
Part of therapeutic strategies aimed at improving quality of life and survival in HBV patients.

Side Or Adverse Effects

Nausea, commonly reported but usually mild and transient.
Dizziness and fatigue leading to tiredness in some patients.
Headache occurring during initial phases of treatment.
Allergic reactions including urticaria, swelling of face, lips, tongue, or throat, which require immediate medical attention.
Potential for lactic acidosis characterized by unusual muscle pain, coldness, dizziness, and difficulty breathing.
Severe liver symptoms including swelling around midsection, upper abdominal pain, loss of appetite, dark urine, clay-colored stools, and jaundice.
Flare-ups or exacerbation of hepatitis B following discontinuation of entecavir therapy.
Elevated liver enzymes indicating possible hepatotoxicity in rare cases.
Possible renal function alterations in patients with pre-existing kidney disease.
Gastrointestinal discomfort and abdominal pain reported infrequently.
Fatigue and malaise that may affect patients’ daily activities.
Risk of immune reconstitution inflammatory syndrome in patients co-infected with HIV.
Low incidence of rash or skin reactions.
Rare instances of pancreatitis and lactic acid elevation documented in post-marketing reports.
Potential worsening of HIV infection if administered in untreated HIV patients.

Precautions

Test for HIV infection prior to initiation to avoid development of HIV resistance.
Take entecavir on an empty stomach, at least 2 hours after a meal and 2 hours before the next meal, to maximize absorption.
Regular monitoring of liver function tests during and after therapy to detect flare-ups or hepatotoxicity.
Dose adjustments are mandatory in patients with renal impairment to prevent drug accumulation and toxicity.
Inform healthcare provider of any history of liver transplant or severe liver disease before starting therapy.
Use caution in patients with a history of lactic acidosis or conditions predisposing to it, like obesity or prolonged antiviral use.
Pregnant patients should be registered in pregnancy registries to monitor potential fetal effects.
Breastfeeding mothers should consult healthcare providers as entecavir is excreted in breast milk.
Avoid abrupt discontinuation of therapy as hepatitis B exacerbations may occur.
Notify physician of any other concomitant medications, including herbal and over-the-counter drugs, to avoid interactions.
Patients should maintain regular follow-up visits to assess therapeutic response and safety.
Educate patients on symptom recognition of lactic acidosis and hepatotoxicity for timely intervention.
Avoid use in patients with untreated HIV to prevent development of resistant strains.
Use caution in pediatric patients; dose should be based on weight and clinical condition.
Maintain proper storage conditions for oral solution to preserve potency and avoid degradation.

Warnings

Contraindicated in patients with untreated HIV infection due to risk of HIV resistance development.
Serious risk of lactic acidosis, a potentially fatal metabolic complication requiring immediate medical attention.
May cause severe liver injury or exacerbation of hepatitis B upon discontinuation; close monitoring required post-therapy.
Risk of immune reconstitution syndrome in co-infected patients leading to clinical deterioration.
Potential for worsening liver function or hepatic failure especially in patients with advanced liver disease.
Pregnancy category: Use only if clearly needed; potential risks should be discussed with healthcare provider.
Renal impairment necessitates careful dosage adjustment to avoid toxic accumulation.
Risk of hypersensitivity reactions including anaphylaxis and severe skin reactions.
Severe hypophosphatemia and peripheral neuropathy reported in rare cases.
Long-term safety in pediatric patients is not fully established; monitor growth and development closely.
Patients should be advised against abrupt withdrawal to minimize risk of hepatitis flare-ups.
Concomitant use with other nephrotoxic or hepatotoxic drugs should be monitored.
Potential for lactic acidosis is increased in patients who are overweight, female, or have extended prior antiviral treatment.
Not effective in preventing transmission of HBV or other infections; safe practices should be maintained.
In patients with prior nucleoside exposure, resistance patterns should be evaluated before starting entecavir.

Contraindication

Hypersensitivity or allergy to entecavir or any components of the formulation.
Presence of untreated HIV infection to avoid development of HIV drug resistance.
Known lactic acidosis or metabolic acidosis at baseline.
Severe hepatic decompensation without close monitoring.
Concurrent use of other antiviral drugs targeting HIV without appropriate antiretroviral therapy.
Pediatric use in children under 2 years or weighing less than 10 kilograms without specialist supervision.
History of hypersensitivity reactions to nucleoside analogues associated with systemic reactions.
Patients with hypersensitivity to excipients in oral solution or tablet formulations.
Severe renal impairment without dose adjustment contraindicated due to risk of toxicity.
Known hypersensitivity to other reverse transcriptase inhibitors rendering entecavir unsafe.
Pregnancy unless benefits outweigh risks and close monitoring is ensured.
Use in lactating women without medical advice since drug passage in breastmilk is documented.
Patients unable to comply with regular monitoring of liver function and viral markers.
Administration to patients with concurrent infections that may mask entecavir-related adverse effects.
Incompatibility with certain antiretroviral regimens, requiring careful treatment planning.

Drug Interactions

Concomitant administration with antiretroviral drugs targeting HIV, such as lamivudine or telbivudine, may affect viral resistance profiles.
No significant cytochrome P450 mediated interactions observed, due to minimal hepatic metabolism.
Co-administration with nephrotoxic agents requires caution to avoid renal toxicity.
Medications that alter renal function or clearance can modify entecavir elimination and necessitate dose adjustments.
Use with immunosuppressive drugs following liver transplantation may require monitoring for additive adverse effects.
Interaction with other antiviral agents may necessitate dosage modifications and close efficacy monitoring.
No reported interactions with common vitamins or herbal supplements, yet patient disclosure of all supplements is essential.
Drugs that prolong QT interval should be monitored due to rare case reports of arrhythmias.
Antacids or medications altering gastric pH may reduce absorption if not separated by recommended administration intervals.
Potential interaction with proton pump inhibitors or H2 antagonists if not dosed apart from entecavir.
Concurrent use of drugs causing lactic acidosis warrants careful observation and symptom monitoring.
Avoid unsupervised combination with other nucleoside analogues to prevent competitive effects or toxicity.
No significant interaction with warfarin or other anticoagulants documented.
Potential interaction with drugs affecting gastrointestinal motility altering absorption rate.
Monitoring required if co-administered with drugs impacting renal tubular secretion.

Preparations Of The Drug

Entecavir oral solution, 0.05 mg/mL, supplied with a calibrated measuring device for accurate dosing.
Entecavir oral tablets available in 0.5 mg strength, typically used in nucleoside-naïve patients.
Entecavir oral tablets available in 1 mg strength, recommended for patients with lamivudine-resistant HBV infection.
Film-coated tablets designed for enhanced stability and ease of swallowing.
Oral solution formulation beneficial for pediatric, elderly, and patients unable to swallow tablets.
Packaging designed to protect from moisture, heat, and light to maintain drug stability.
Expiry dates clearly marked; unused liquid medication should be discarded after expiration.
Combination with appropriate measuring syringes or devices for pediatric dosing.
Storage instructions recommend room temperature storage, tightly closed container to prevent contamination.
No known fixed-dose combination products currently available with entecavir.
Preparation free from preservatives that may cause allergic reactions in sensitive individuals.
Tablets may be scored to facilitate dose adjustments as per clinical condition if prescribed.
Manufactured under strict quality control to ensure pharmaceutical grade consistency.
Available under the brand name Baraclude with patient information leaflets for education.
Different formulations allow flexible dosing regimens tailored to individual patient needs.